Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market
Shares of Bristol Myers Squibb Co. BMY inched 0.90% higher to $55.95 Tuesday, on what proved to be an all-around positive ...
Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...
MarketBeat on MSN12h
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...
Business Insider1d
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...